Plain-English translation of NCT06095141 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a chemotherapy drug, for people with advanced pancreatic cancer whose tumors have a specific genetic condition called homologous recombination deficiency (HRD). These patients have already tried at least one other chemotherapy treatment that didn't stop their cancer from growing. The study wants to see if the medication can slow down cancer growth and improve survival.
Pancreatic cancer is very difficult to treat, and most patients are diagnosed after the cancer has spread. While chemotherapy helps some patients, researchers have found that patients with certain genetic changes in their tumors—called HRD—may respond especially well to platinum-based drugs like . This study is designed to formally test whether the medication works well specifically for this genetic subgroup of patients whose previous treatments have not worked.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive intravenously (through an IV) on a regular schedule as part of your cancer treatment. Your research team will monitor how you're doing and how your cancer is responding through blood tests and imaging scans every four weeks. The study is enrolling about 30 patients and is still actively recruiting, so the exact length of your participation will depend on how your body responds to the treatment and what your doctors recommend.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Fudan University
Enrollment target
~30 participants
Started
December 2023
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ying Yang, MD
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.